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Executive Summary 2016 
 
The 2016 Integrated HIV/AIDS, STD, and Viral Hepatitis Surveillance Report provides data on 
infections reported to the Massachusetts Department of Public Health (MDPH) Bureau of 
Infectious Disease and Laboratory Sciences by healthcare providers and laboratories per 
regulation (105 CMR 300.000). This report focuses on a subset of these diseases:  
 Chlamydia 
 Gonorrhea 
 Hepatitis B 
 Hepatitis C 
 HIV/AIDS 
 Syphilis 
 
The intended audience for this annual surveillance report includes the clinicians and laboratory 
professionals who report cases, as well as the community organizations, local public health 
departments, advocates, policymakers, and researchers who are interested in the health of 
Massachusetts residents. 
 
Key highlights in 2016  
 
Chlamydia, gonorrhea, and syphilis: 
 Chlamydia continues to be the most commonly reported infectious disease, with 
approximately 24,000 to 26,000 cases reported annually since 2012. 
 Gonorrhea is now clearly reported disproportionately in men, among whom rates 
have more than doubled over the last decade.  
 The incidence rate of infectious syphilis (primary, secondary, and early latent 
syphilis) has increased 30%, to a ten-year high of 15.2 per 100,000 population in 
2016.  Syphilis continues to disproportionally affect men, reflecting an ongoing 
epidemic among men who have sex with men. 
 Young adults (ages 15–29 years) have the highest rates of chlamydia, gonorrhea, and 
syphilis, compared to other age groups. 
 
HIV/AIDS:1 
 The number of HIV infection diagnoses decreased by 25% from 2006 (N=834) to 
2015 (N=627). Due to ongoing transmission as well as improved survival and lower 
rates of death, the number of persons known to be living with HIV/AIDS in 
Massachusetts increased 25% between 2006 (N=16,218) and 2015 (N=20,253). 
 Black (non-Hispanic) and Hispanic/Latino residents had significantly higher rates of 
HIV infection diagnoses compared to white (non-Hispanic) residents. This was most 
notable among women, as 76% of women newly diagnosed between 2013 and 2015 
were black (non-Hispanic) or Hispanic/Latina. 
                                                 
1 Due to the extensive follow up required to verify date of diagnosis, all HIV/AIDS data reflect HIV infection 
diagnosed through 2015. 
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 Male-to-male sex remained the single most frequently reported exposure mode 
among newly diagnosed cases of HIV infection, and represented 60% of newly 
diagnosed cases among men during 2013 to 2015. 
 
Hepatitis B and C: 
 Reported confirmed cases of chronic hepatitis B continued to decline, due in large 
part to near-universal infant immunization in the United States.  
 An average of over 8,500 confirmed and probable hepatitis C cases were reported in 
each of the past nine years (2007 to 2015).  
 There continued to be an increase of hepatitis C cases reported among adolescents 
(age 15–24 years) and young adults (age 25–29 years), reflecting ongoing 
transmission among young people injecting opioids. 
 
This report was developed by the following MDPH staff: 
 
Katherine Hsu, MD, MPH, Medical Director, Division of STD Prevention and HIV/AIDS 
Surveillance 
Betsey John, MPH, Director, HIV/AIDS and STD Surveillance 
Shauna Onofrey, MPH, Viral Hepatitis Surveillance Coordinator, Division of Epidemiology and 
Immunization 
Kathleen Roosevelt, MPH, Director, Division of STD Prevention 
Patricia Kludt, MPH, Director, Epidemiology Program  
Gillian Haney, MPH, Director, Office of Integrated Surveillance and Informatics Services 
H. Dawn Fukuda, ScM, Director, Office of HIV/AIDS 
Larry Madoff, MD, Director, Division of Epidemiology and Immunization 
Alfred DeMaria, Jr., MD, Medical Director and State Epidemiologist, Bureau of Infectious 
Disease and Laboratory Sciences 
Kevin Cranston, MDiv, Director, Bureau of Infectious Disease and Laboratory Sciences 
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CHLAMYDIA 
 
 
 
 26,448 cases of chlamydia were reported in Massachusetts in 2016 - making it the most 
frequently reported infection in the Commonwealth.    
 The total number of reported chlamydia cases increased by 60% from 16,569 in 2007 to 
26,448 in 2016. 
 In 2016, the chlamydia incidence rate among women (488.1 per 100,000) was nearly 
twice as high as the rate among men (282.4 per 100,000). 
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 The five jurisdictions with the highest chlamydia incidence rates were Provincetown, 
(1,631.5 per 100,000), Lawrence (1,200.6 per 100,000), Brockton (922.1 per 100,000), 
Boston (860.3 per 100,000), and Springfield (827.1 per 100,000). 
 In 2016, the statewide chlamydia incidence rate of 388.3 per 100,000 population was lower 
than the national rate of 497.3 per 100,000.2  
 Massachusetts ranked tenth lowest in chlamydia incidence among the 50 states. 2   
 
  
                                                 
2 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2016. Atlanta: U.S. Department of 
Health and Human Services; 2017 
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CHLAMYDIA 
 
 
 The chlamydia incidence rate remained highest among adolescents and young adults.  
 In 2016, the chlamydia incidence rate among young adults (ages 20–24) was over five times 
higher than the statewide rate among all ages (2,098.8 compared to 388.3 per 100,000).  
 The rate among adolescents (ages 15–19) was over three times higher than the statewide rate 
among all ages (1,286.7 compared to 388.3 per 100,000). 
 
Additional information about chlamydia and other STDs is available online at 
www.mass.gov/dph/cdc/std. 
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GONORRHEA 
 
 4,617 gonorrhea cases were reported in 2016.  
 The total number of reported gonorrhea cases increased by 69% from 2,724 in 2007 to 4,617 
in 201.  
 Between 2007 and 2016, the gonorrhea incidence rate reported among men more than 
doubled (from 45.7 per 100,000 to 101.5 per 100,000). The gonorrhea incidence rate among 
men is now nearly three times higher than the rate among women (36.0 per 100,000).  
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 Gonorrhea cases were clustered in urban areas in 2016. 
 The five cities with the highest rates were Provincetown (1,257.7 per 100,000), Brockton 
(235.6 per 100,000), Boston (212.4 per 100,000), Springfield (173.8 per 100,000), and New 
Bedford (155.7 per 100,000). 
 The statewide incidence rate of 67.8 per 100,000 was less than half the national rate of 145.8 
per 100,000.2  
 Massachusetts ranked ninth lowest in gonorrhea incidence rate among the 50 states.2 
 
 
 
 
 
 
 
 
 
 
 
2 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2016. Atlanta: U.S. Department of 
Health and Human Services; 2017  
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GONORRHEA 
 
 The gonorrhea incidence rate remained highest among young adults, and has increased since 
2011 in the 20–39 year old population.  
 In 2016, the gonorrhea incidence rate among young adults (ages 20–24) was nearly four 
times the statewide incidence rate among all ages (249.3 compared to 67.8 per 100,000). 
 The rate among young adults (ages 25–29) was three times higher than the statewide rate 
among all ages (216.9 compared to 67.8 per 100,000).  
  
Additional information about gonorrhea and other STDs is available online at 
www.mass.gov/dph/cdc/std. 
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SYPHILIS  
 
 1,033 infectious syphilis (primary, secondary, and early latent) cases were reported in 2016. 
 The total number of reported infectious syphilis cases in 2016 (N=1,033) was nearly four 
times the number reported in 2007 (N=268). 
 Between 2007 and 2016, the syphilis incidence rate reported among men more than tripled 
(from 7.8 to 28.9 per 100,000). The syphilis incidence rate among men is now nearly 13 
times higher than the rate among women (2.3 per 100,000).  
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 The highest infectious syphilis incidence rates were in Suffolk (47.6 per 100,000) and 
Barnstable (17.1 per 100,000) counties. 
 The statewide infectious syphilis incidence rate increased from 4.2 per 100,000 in 2007 to a 
ten-year high of 15.2 per 100,000 in 2016.  
 Massachusetts ranked 18th in primary and secondary syphilis incidence rate among the 50 
states.2 
 
 
 
 
 
 
 
 
 
 
2 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2016. Atlanta: U.S. Department of 
Health and Human Services; 2017  
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SYPHILIS 
 
 
 In 2016, the infectious syphilis incidence rate was highest among individuals aged 25 to 29 
years, followed by individuals 20 to 24 years, and 30 to 39 years. 
 In 2016, the infectious syphilis incidence rates among individuals aged 25 to 29 years, 20 to 
24 years, and 30 to 39 years were all approximately double the overall statewide incidence 
rate among all ages (40.1, 35.7, and 30.1, respectively, compared to 15.2 per 100,000).   
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 In 2016, the infectious syphilis incidence rate was nearly four times higher among both the 
black (non-Hispanic) population (36.7 cases per 100,000) and the Hispanic/Latino population 
(34.8 cases per 100,000) compared to the white (non-Hispanic) population (9.8 cases per 
100,000).   
Additional information about infectious syphilis is available online at 
www.mass.gov/dph/cdc/std. 
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HIV/AIDS  
 
 
 The number of people known to be living with HIV infection in Massachusetts increased by 
25% from 16,218 on December 31, 2006 to 20,253 on December 31, 2015.  
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 In 2015, there were 627 HIV infections diagnosed and 273 deaths among people reported 
with HIV infection in Massachusetts.  
 The number of HIV infection diagnoses decreased by 25% from 2006 (N=834) to 2015 
(N=627).  
 The number of deaths among people reported with HIV/AIDS decreased by 16% from 324 in 
2005 to 273 deaths in 2015.  
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 Of the 351 cities and towns in Massachusetts, 206 (59%) had at least one reported HIV 
infection diagnosis from 2013 to 2015.   
 The majority of HIV infection diagnoses were reported among people living in large urban 
areas, with the exception of Provincetown.  
 Of those cities and towns where HIV infections were diagnosed within the three-year period 
2013 to 2015, the majority (87%) had rates under ten per 100,000 population.  
 Provincetown was the only locality with a rate of over 100 per 100,000 during this time 
period. 
 Other areas with higher incidence rates were clustered in and around major cities such as 
Boston, Worcester, and Springfield.   
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HIV/AIDS 
 
 
 From 2013 to 2015, of the 1,994 HIV infections newly diagnosed in Massachusetts, 1,477 
(73%) were among men and 517 (27%) were among women.   
 Among men, the largest proportion of newly diagnosed HIV infections were among white 
(non-Hispanic) men, whereas among women the majority of newly diagnosed HIV infections 
were among black (non-Hispanic) women. 
 With age-adjusted annual average rates of HIV diagnosis during 2013 to 2015 of 47.0 and 
30.5 cases per 100,000 population, black (non-Hispanic) and Hispanic/Latino individuals 
were diagnosed at rates 10 and 6 times that of white (non-Hispanic) individuals (4.8 per 
100,000), respectively.  
o Among women, the disparity was more pronounced: the age-adjusted annual average 
rate of HIV diagnosis during 2013 to 2015 among black (non-Hispanic) women (40.0 
per 100,000) was 27 times, and among Hispanic/Latina women (14.5 per 100,000) 
was 10 times that of white (non-Hispanic) women (1.5 per 100,000).  
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 From 2013 to 2015, the primary risk reported for newly diagnosed HIV infection in 
Massachusetts was male-to-male sex (44%). A substantial proportion of diagnoses were 
reported with No Identified Risk (28%).3 
 
 
  
                                                 
3 The category of presumed heterosexual is used exclusively for women, to define HIV exposure mode among cases 
when sex with men is the only reported risk factor for HIV infection. 
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 Since the mid-1990’s, there has been a dramatic reduction in mother-to-child transmission of 
HIV infection related to high rates of antiretroviral treatment of HIV+ women, and progress 
in HIV screening during pregnancy.  
 From 2006 to 2015, the number of HIV-infected newborns remained between zero and four 
cases annually, with no cases identified in 2015.   
Additional information about HIV/AIDS is available online through the MDPH HIV/AIDS 
Epidemiologic Profile at  www.mass.gov/dph/cdc/aids. 
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VIRAL HEPATITIS – HEPATITIS B 
 
 
 An average of 1,863 [range: 1,621 (2013) – 2,110 (2007)] confirmed and probable chronic 
hepatitis B virus (HBV) infection cases were reported each year from 2007 to 2015. 
 In 2015, 870 confirmed chronic HBV infection cases were reported. An additional 983 
probable cases were reported for a total of 1,853 confirmed and probable HBV cases. 
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 The incidence of newly diagnosed confirmed and probable chronic HBV infection cases 
among men decreased from 37.8 per 100,000 in 2007 to 32.0 per 100,000 in 2015. The 
incidence of newly diagnosed chronic HBV infection among women decreased from 28.1 per 
100,000 in 2007 to 22.9 per 100,000 in 2015. 
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 While 184 confirmed and suspect acute HBV infection cases were reported in 2007, an 
average of 130 [range: 121 (2015) – 140 (2014)] confirmed and suspect acute HBV cases 
were reported each year from 2008 to 2015. 
 In 2015, there were 27 confirmed acute and 94 suspect acute HBV cases for a total of 121 
acute cases.   
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VIRAL HEPATITIS - HEPATITIS C 
 
 
 The annual number of newly diagnosed confirmed and probable hepatitis C cases reported in 
Massachusetts since 2007 remained high with about 8,000 to 9,000 cases reported each year.   
 There were 6,095 confirmed and 2,947 probable hepatitis C cases reported to MDPH in 
2015, for a total of 9,042.   
 Please note, in 2016, revised case definitions for acute and chronic HCV infection were 
implemented that will contain significant changes from the previous case definitions which 
apply to data presented here. For further information see 
https://wwwn.cdc.gov/nndss/conditions/ . 
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VIRAL HEPATITIS - HEPATITIS C 
 
 
 
 In 2007, reported cases of hepatitis C were distributed in a curve with two age peaks, with 
the lower peak at age 28 years and the higher peak at age 50 years.  
 In 2015, the reported cases were again distributed in a bi-modal curve, but with the higher 
peak at age 26 years and the lower peak at age 57 years. 
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 Fifty-three percent of confirmed and probable hepatitis C infection cases in those less than 30 
years of age were men, and 47% were women. 
 The majority of new hepatitis C infections among persons less than 30 years of age were 
attributable to blood exposure through injection drug use. 
 Sixty percent of confirmed and probable hepatitis C infection cases in those 30 years of age 
and older were men, and 40% were women. 
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SPECIFIC POPULATIONS: ADOLESCENTS & YOUNG ADULTS 
 
 
 
 In 2016, in Massachusetts, 61% of chlamydia cases and 39% of gonorrhea cases were 
reported among adolescents and young adults aged 15–24 years.  
o Nationally in 2016, 63% of chlamydia cases and 47% of gonorrhea cases were 
reported among adolescents and young adults aged 15–24 years.4   
  
                                                 
4 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2016. Atlanta: U.S. Department of 
Health and Human Services; 2017 
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 During 2013 to 2015, 14% of HIV infection diagnoses were reported among 
adolescents and young adults aged 15–24 years.   
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 The racial/ethnic distribution of adolescents and young adults (aged 15–24 years) 
diagnosed with HIV infection was: white (non-Hispanic) (30%), black (non-Hispanic) 
(31%), Hispanic/Latino (35%), and other (4%).  
2016 Integrated HIV/AIDS, STD, and Viral Hepatitis Surveillance Report 
Massachusetts Department of Public Health 
 
  - 28 - 
 
 
 During 2013 to 2015, the primary exposure mode for HIV infection among 
adolescents and young adults was male-to-male sex (59%), followed by presumed 
heterosexual sex (12%), heterosexual sex  (5%), injection drug use (3%), and all other 
exposure modes (2%). Sixteen percent of adolescents and young adults were reported 
with no identified risk (NIR) for HIV exposure.
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 The age distribution of hepatitis C virus 
(HCV) cases reported in Massachusetts 
changed between 2002 and 2015 with a 
significant increase in cases among young 
persons who inject drugs.  
 In 2002, reported HCV cases were 
distributed in a curve with one age peak 
at 45 years.  
 By 2007, the development of a second 
epidemic among younger persons became 
apparent, as reported cases were 
distributed in a bi-modal curve with one 
peak at 25 years of age and a second peak 
at 50 years. 
 In 2015, HCV cases among young 
persons who inject drugs outnumbered 
newly reported cases among the older age 
(“baby boomer”) cohort. 
 The proportion of cases among young 
women (aged 15–24 years) was higher in 
2007 (55%, N=425/771) and 2015 (52%, 
N=457/886) compared to 2002 (46%, 
N=206/446). 
 The primary risk for hepatitis C infection 
in younger adults is injection drug use.  
Thus far, a similar epidemic of HIV 
infection in this population has not been 
identified, most likely because of low 
prevalence of HIV infection among 
young people who use drugs in recent 
years.  However, introduction of HIV 
infection among injecting drug using 
networks could lead to increased 
incidence of HIV infection in this 
population.  
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Reported Sexual Behaviors Among Massachusetts High School Students, 
2007–20151 
 Percentage who reported: 
2007 2009 2011 2013 2015 
Ever having sexual intercourse 44 46 42 38 36 
Having sexual intercourse before age 13 6 5 4 3 3 
Having had sexual intercourse with 4+ 
partners during their life  
12 13 11 9 8 
Ever injecting an illegal drug 3 2 2 1 1 
Using a condom at last sexual intercourse 61 58 58 58 63 
Ever being taught about HIV/AIDS in school 89 87 84 85 80 
1 Unweighted sample size by year: 2007 (N=3,131), 2009 (N=2,707), 2011 (N=2,729), 2013 (N=2,718), 2015 (N=5,738)  
Data Source: Massachusetts Department of Elementary and Secondary Education, Massachusetts Youth Risk Behavior Survey 
 
 
 The Massachusetts Youth Risk Behavior Survey (MYRBS) is performed biennially 
among a sample of ninth to twelfth grade students.   
 Three indicators of high risk youth sexual behavior (ever having sexual intercourse, 
having sexual intercourse before age 13 years, having had sexual intercourse with 
four or more partners during their life) reached their lowest levels in 2015 (36%, 3%, 
and 8%, respectively).  
 Lifetime injection drug use remained at a low of 1% in 2015.  
 One protective correlate of sexual behavior, ever being taught about HIV/AIDS in 
school, declined to a low of 80% in 2015. 
 Using a condom at last sexual intercourse increased to 63% in 2015. 
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SPECIFIC POPULATIONS: WOMEN 
 
 
 
 Unlike gonorrhea, chlamydia infection in Massachusetts is more commonly diagnosed 
and reported among women. Routine screening for chlamydia infection is recommended 
for asymptomatic, sexually active women age 24 years and younger and among older 
women who are at increased risk for infection by the U.S. Preventive Services Task Force 
(USPSTF).5 
 From 2007 to 2016, the number of chlamydia cases reported among women increased by 
43% (from 11,968 to 17,062). 
 The number of chlamydia cases reported among men doubled from 2007 (N=4,584) to 
2016 (N=9,307). Routine screening is not currently recommended by the USPSTF for all 
sexually active men. 
 
  
                                                 
5 Published Recommendations. U.S. Preventive Services Task Force. 
https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations 
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 In 2016, 65% of reported chlamydia cases were among women (N=17,062) and 35% 
were among men (N=9,307).   
 In 2016, 27% of reported gonorrhea cases were among women (N=1,258) and 73% were 
among men (N=3,346).   
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Chlamydia and Gonorrhea Screening: 
Since 1997, the Division of STD Prevention has partnered with other agencies to reduce pelvic 
inflammatory disease, infertility and other health consequences of chlamydia and gonorrhea 
infection through screening and treatment of women who are at higher risk for infection. 
 In 2016, specimens collected from reproductive age women (16 to 44 years) were tested 
at the Massachusetts State Public Health Laboratory for chlamydia and gonorrhea 
infection, with 7.5% and 1.1% positivity, respectively.  
 
 Test results from selected sites have yielded the following:    
 
Chlamydia & Gonorrhea Screening Projects, Percent Positive for 
Infection Among Women of Reproductive Age, Massachusetts, 2016* 
 
Site Type Number 
tested 
Percent 
positive for 
chlamydia 
Percent 
positive for 
gonorrhea 
School-Based Health Centers 1,165 9% <1% 
Correctional Facilities 1,823 7% 3% 
Family Planning Clinics 980 9% 1% 
Hospital Based Clinic 1,089 7% 1% 
Expanded STD Screening 
Sites* 
8,136 7% 1% 
Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences 
*Includes reproductive age women (aged 16 to 44 years), tested at Prevention, Integrated Counseling, Screening, and Referral 
sites under former IPP funding now known as Safety Net Services. 
 
  
2016 Integrated HIV/AIDS, STD, and Viral Hepatitis Surveillance Report 
Massachusetts Department of Public Health 
 
  - 34 - 
Congenital Syphilis Prevention: 
 
 
 
 In 2016, there were three reported cases of congenital syphilis6 in Massachusetts and the 
congenital syphilis rate was 4.2 cases per 100,000 live births. 
 The recent increase in reported congenital syphilis cases parallels increases in infectious 
syphilis being reported among reproductive aged women (15–49 years) in Massachusetts. 
 This mirrors national trends, where after a period of decline from 2008 to 2012, congenital 
syphilis rates increased by 87% between 2012 and 2016 (from 8.4 to 15.7 cases per 100,000 
live births).7  
 The few cases of congenital syphilis occurring in Massachusetts were born to women with 
little or no prenatal care, or women who were not known to be at high risk for syphilis 
infection, and therefore did not receive repeat syphilis screening in the third trimester or at 
delivery. 
 
  
                                                 
6 A condition caused by infection in utero with Treponema pallidum. A wide spectrum of severity exists, from 
inapparent infection to severe cases that are clinically apparent at birth. For more information see 
http://www.cdc.gov/std/stats/congenitalsyphilisdef-rev-jan-2015.pdf 
 
7 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2016. Atlanta: U.S. 
Department of Health and Human Services; 2017. 
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 During 2013 to 2015, presumed heterosexual sex (50%) was the predominant exposure 
mode for women diagnosed with HIV infection in Massachusetts, followed by 
heterosexual sex (15%), injection drug use (8%), and other exposure modes (1%). 
Twenty-six percent of women were reported with no identified risk for HIV exposure.  
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 During 2013 to 2015, 51% of women diagnosed with HIV infection were born outside of 
the U.S.  Among men diagnosed with HIV infection during 2013 to 2015, only 31% were 
born outside of the U.S. 
 Women born outside the United States, and recently diagnosed with HIV infection in 
Massachusetts, were primarily from sub-Saharan Africa (46%), the Caribbean (34%), and 
Central or South America (13%).  
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SPECIFIC POPULATIONS: RACIAL/ETHNIC MINORITIES 
 
 
 
 In 2016, black (non-Hispanic) and Hispanic/Latino individuals represented 7% and 11% 
of the total Massachusetts population, and 17% and 26% of infectious syphilis cases 
(with known race/ethnicity), respectively.  
 During 2013 to 2015, black (non-Hispanic) and Hispanic/Latino individuals represented 
30% and 28% of individuals diagnosed with HIV infection in Massachusetts, 
respectively.  
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 In Massachusetts, in 2017, the age-adjusted HIV infection prevalence rate among the 
black (non-Hispanic) population (1,559 per 100,000) was 11 times greater, and among 
the Hispanic/Latino population (1,105 per 100,000) was 8 times greater than among the 
white (non-Hispanic) population (143 per 100,000).  
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SPECIFIC POPULATIONS: MEN WHO HAVE SEX WITH MEN 
 
 
 
 Of the 1,030 infectious syphilis cases reported in 2016, 682 (66%) were among men who 
reported having sex with men (MSM). 
 The proportion of infectious syphilis cases among MSM was above 65% from 2007 to 
2016. 
 From 2007 to 2016, the number of reported infectious syphilis cases among MSM more 
than tripled, from 184 to 682.  
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 The racial/ethnic distribution of MSM reported with infectious syphilis in 2016 was: 
white (non-Hispanic) (48%), Hispanic/Latino (23%), black (non-Hispanic) (15%), and 
other (10%). An additional 4% of cases were reported with unknown race/ethnicity.  
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 In 2016, 44% (N=302) of infectious syphilis cases among men reporting sex with men, 
also reported that they were co-infected with HIV.   
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 During 2013 to 2015, male-to-male sex was the predominant exposure mode (60%) for 
men diagnosed with HIV infection in Massachusetts. Twenty-nine percent of men were 
reported with no identified risk for HIV exposure, some of whom may be MSM. 
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 Among men, the proportion of HIV infection diagnoses with male-to-male sex as the 
reported mode of exposure remained between 54% and 62% from 2006 to 2015. During 
the same time period, the proportion reported with no identified risk increased from 22% 
to 30%. 
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Strengths and Limitations of Data 
 
  
HIV/AIDS Case Data 
 
STD Case Data 
 
Viral Hepatitis Case Data 
Description 
 
 Collected by MDPH Bureau of Infectious Disease and Laboratory Sciences 
 Reported statewide. 
 All laboratories and healthcare providers are required by law to report.  
 Includes individuals first 
diagnosed with HIV 
infection in MA. 
 Includes individuals first 
reported as living in MA. 
 Includes individuals first 
reported as living in MA. 
Strengths  Completeness of 
race/ethnicity data is high. 
 All clinical laboratories in 
MA report electronically 
resulting in more complete 
and timely reporting of 
disease. 
 Data are estimated to be 
99% complete. 
 All clinical laboratories in 
MA report electronically 
resulting in more complete 
and timely reporting of 
disease. 
 Most infectious syphilis 
cases agree to interview, 
resulting in reasonably 
complete race/ethnicity 
and sex of sex partner 
data. 
 All clinical laboratories in 
MA report electronically 
resulting in more complete 
and timely reporting of 
disease. 
Limitations  Due to follow up 
conducted to verify 
accurate date of diagnosis, 
annual incidence data are 
released a year after the 
close of the year. For 
example, 2016 HIV 
diagnoses through 
December 31, 2016 will 
be released on January 1, 
2018. 
 Race/ethnicity data are 
incomplete for gonorrhea 
and chlamydia cases. 
 Sex of sex partner is not 
routinely collected for 
gonorrhea and chlamydia 
cases. 
 Bias is introduced for 
some STDs, such as 
chlamydia infection, 
where screening of 
asymptomatic persons 
occurs more frequently 
among women than 
among men. 
 Race/ethnicity data are 
incomplete. 
 Risk history data are 
not collected on 
chronic HBV cases. 
Massachusetts Youth Risk Behavior Survey  
Description The Massachusetts Youth Risk Behavior Survey (MYRBS) is conducted every two years 
through a collaborative effort between the Massachusetts Department of Elementary and 
Secondary Education (ESE) and Department of Public Health (DPH) to monitor health 
indicators, behaviors, and risk factors contributing to the leading causes of morbidity, 
mortality, and social and academic problems among adolescents.  
Strengths A two-stage sampling method is used to produce representative samples of students in grades 
9 – 12. Response rates are high.  
Limitations All data collected for the MYRBS and the MYHS are based on self-report from students. 
Self-reported data may be subject to error for several reasons, including inaccurate recall of 
events. 
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Interpreting HIV/AIDS, STD, and Viral Hepatitis Data 
Hepatitis B surveillance data are current as of October 5, 2017, hepatitis C data are as of August 
9, 2017, HIV/AIDS data are as of January 1, 2017 and STD data are as of June 16, 2017. All data 
are subject to change. 
I.  HIV/AIDS Exposure Mode Definitions 
The HIV/AIDS exposure mode indicates the most probable risk behavior associated with HIV 
infection.  Assignment of exposure mode is done in accordance with Centers for Disease Control and 
Prevention (CDC) guidelines when multiple exposure modes are reported.  Following is a description 
of the exposure mode categories: 
 MSM (Male to Male Sex):  Includes males who report sexual contact with other 
males, and males who report sexual contact with both males and females. Please note the 
acronym MSM is also used to refer to “men who have sex with men”. 
 IDU (Injection Drug Use):  Cases among persons who report injection drug use. 
 MSM/IDU:  Cases among males who report both injection drug use and sexual contact 
with other males. 
 Heterosexual Sex:  Cases among persons who report specific heterosexual sex with a 
person   with, or at increased risk for, HIV infection (e.g. an injection drug user).  The sub-
categories for this mode of transmission are listed below. 
o Heterosexual Sex w/ an Injection Drug User 
o Heterosexual Sex w/ a person w/ HIV infection or AIDS 
o Heterosexual Sex w/ Bisexual male 
o Other Heterosexual Sex:  Includes all other sub-categories of risk, such as heterosexual 
contact with a person infected through a blood transfusion. 
 Presumed Heterosexual:  Cases among females who report heterosexual sex but do 
not report any other personal risk or any knowledge of specific risk among their male sex 
partners.  As of January 1, 2011, males who were previously grouped in this 
category are categorized as No Identified Risk.  Presumed heterosexual is an exposure 
mode category used by the Massachusetts HIV/AIDS Surveillance Program.  The CDC 
categorizes these cases as No Identified Risk. 
 Pediatric:  Infection before the age of 13 years, including mother to child transmission 
through pregnancy, childbirth or breastfeeding and blood transfusions to children. 
 NIR (No Identified Risk):  Cases among persons with no reported history of exposure to 
HIV through any of the listed exposure categories.  Follow-up is conducted to determine risk for 
those cases that are initially reported without a risk identified.  Includes cases among males 
who were previously categorized in Massachusetts as Presumed Heterosexual. 
 
II.  References to Newly Diagnosed HIV Infections 
Due to the extensive follow up required to verify accurate date of diagnosis, all HIV/AIDS data 
reflect HIV infections diagnosed through 2015.  Newly diagnosed HIV infections/cases include 
all persons diagnosed with HIV from 2013 to 2015, including those who were concurrently or 
subsequently diagnosed with AIDS. All HIV data are presented by the year of diagnosis, not the 
year of report. 
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III.  Race/Ethnicity of STD and HIV/AIDS Cases 
Race/ethnicity references to white residents and black residents represent persons who are white non-
Hispanic and black non-Hispanic, respectively.  All references to Hispanic/Latino for race/ethnicity 
represent persons of Hispanic/Latino heritage regardless of race.  
IV.  STD Case Reports and Analyses 
All information on STD cases reflect year of report and all incidence calculations represent crude 
rates. The source of denominators for calculating rate trends was: Intercensal Estimates of the 
Resident Population by Sex and Age for Massachusetts: April 1, 2000 to July 1, 2010 (ST-
EST00INT-02-25); Source: U.S. Census Bureau, Population Division; Release Date: October 
2012 and Annual Estimates of the Resident Population for Selected Age Groups by Sex for the 
United States, States, Counties and Puerto Rico Commonwealth and Municipios: April 1, 2010 
to July 1, 2016, Source: U.S. Census Bureau, Population Division; Release Date: June 2017.  
The source of denominators for calculating rate maps was the 2010 US Census. The distribution 
of STD cases in incidence rate calculations with unknown values for race/ethnicity has changed 
compared to previous reports.  Cases with unknown values are now redistributed proportionally 
based on the distribution of cases with known values. Due to this change, STD incidence rates by 
race/ethnicity are slightly higher for all years than previously reported.  
 
V. Cell suppression methodology: 
Values less than five are suppressed for denominator populations less than 50,000 or for 
unknown values. Additional values may be suppressed to prevent back calculation. 
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HIV/AIDS, STD, and Viral Hepatitis Case Classifications (in the time period 
of the data in this report) 
HIV INFECTION 
 
Clinical description: HIV (human immunodeficiency virus) is a retrovirus with two serologically 
and geographically distinct species: HIV-1 and HIV-2. It is spread via person-to-person 
transmission through: sexual contact, the use of HIV-contaminated needles and syringes, vertical 
transmission from mother to infant, or the transfusion of contaminated blood or its components. 
HIV attacks the body’s immune system, making the person more likely to get infections or 
infection-related cancers. These opportunistic infections or cancers take advantage of the 
weakened immune system and signal that the person has AIDS (acquired immunodeficiency 
syndrome), the advanced stage of HIV infection. 
 
Case Classification 
Confirmed: Positive HIV-1, Positive HIV-2, or Positive (Undifferentiated) HIV result from a 
differentiating immunoassay, Western Blot, IFA, or culture; Positive/Detected Qualitative HIV 
NAT (DNA or RNA); Quantitative HIV NAT (detectable viral load assay) or physician verified 
diagnosis. 
 
 
Sexually transmitted diseases (STD) 
 
Chlamydia trachomatis, Infection (Revised 6/09)  
 
Clinical description:  Infection with Chlamydia trachomatis may result in urethritis, 
epididymitis, cervicitis, acute salpingitis, or other syndromes when sexually transmitted; 
however, the infection is often asymptomatic among women. Perinatal infections may result in 
inclusion conjunctivitis and pneumonia among newborns. Other syndromes caused by C. 
trachomatis include lymphogranuloma venereum (see Lymphogranuloma Venereum) and 
trachoma.  
 
Laboratory criteria for diagnosis 
• Isolation of C. trachomatis by culture or  
• Demonstration of C. trachomatis in a clinical specimen by detection of antigen or nucleic acid  
 
Case classification  
 
Confirmed: a case that is laboratory confirmed  
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Gonorrhea (effective January 1, 2014)  
 
Clinical description: A sexually transmitted infection commonly manifested by urethritis, 
cervicitis, proctitis, salpingitis, or pharyngitis. Infection may be asymptomatic.  
 
Laboratory Criteria for Diagnosis  
• Observation of gram-negative intracellular diplococci in a urethral smear obtained from a male 
or an endocervical smear obtained from a female, or  
• Isolation of typical gram-negative, oxidase-positive diplococci by culture (presumptive 
Neisseria gonorrhoeae) from a clinical specimen, or  
• Demonstration of N. gonorrhoeae in a clinical specimen by detection of antigen or nucleic acid  
 
Case Classification  
Probable: demonstration of gram-negative intracellular diplococci in a urethral smear obtained 
from a male or an endocervical smear obtained from a female. 
Confirmed: a person with laboratory isolation of typical gram-negative, oxidase-positive 
diplococci by culture (presumptive Neisseria gonorrhoeae) from a clinical specimen, or 
demonstration of N. gonorrhoeae in a clinical specimen by detection of antigen or detection of 
nucleic acid via nucleic acid amplification (e.g., PCR) or hybridization with a nucleic acid probe.  
 
Syphilis (effective Jan 1, 2014)  
 
Syphilis is a complex sexually transmitted infection that has a highly variable clinical course. 
Adherence to the following surveillance case definitions will facilitate understanding the 
epidemiology of this disease across the U.S.  
 
Syphilis, primary  
 
Clinical description: A stage of infection with Treponema pallidum characterized by one or more 
ulcerative lesions (e.g. chancre), which might differ considerably in clinical appearance.  
 
Laboratory criteria for diagnosis:  
Demonstration of T. pallidum in clinical specimens by darkfield microscopy, or by polymerase 
chain reaction (PCR) or equivalent direct molecular methods.  
 
Case classification  
 
Probable: a case that meets the clinical description of primary syphilis with a reactive serologic 
test (nontreponemal: Venereal Disease Research Laboratory [VDRL], rapid plasma reagin 
[RPR], or equivalent serologic methods; treponemal: fluorescent treponemal antibody absorbed 
[FTA-ABS], T. pallidum particle agglutination [TP-PA], enzyme immunoassay [EIA], 
chemiluminescence immunoassay [CIA], or equivalent serologic methods).8 
 
Confirmed: a case that meets the clinical description of primary syphilis that is laboratory 
confirmed  
                                                 
8 These treponemal tests supersede older testing technologies, including microhemagglutination assay for antibody 
to T. pallidum [MHA-TP]. 
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Syphilis, secondary  
 
Clinical description: A stage of infection caused by T. pallidum characterized by localized or 
diffuse mucocutaneous lesions (e.g., rash — such as non-pruritic macular, maculopapular, 
papular, or pustular lesions), often with generalized lymphadenopathy. Other symptoms can 
include mucous patches, condyloma lata, and alopecia. The primary ulcerative lesion may still be 
present. Because of the wide array of symptoms possibly indicating secondary syphilis, serologic 
tests for syphilis and a thorough sexual history and physical examination are crucial to 
determining if a case should be classified as secondary syphilis.  
 
Laboratory criteria for diagnosis:  
• Demonstration of T. pallidum in clinical specimens by darkfield microscopy, or by polymerase 
chain reaction (PCR) or equivalent direct molecular methods  
 
Case classification  
 
Probable: a case that meets the clinical description of secondary syphilis with a nontreponemal 
(VDRL, RPR, or equivalent serologic methods) titer ≥4 AND a reactive treponemal test (FTA-
ABS, TP-PA, EIA, CIA, or equivalent serologic methods.  
 
Confirmed: a case that meets the clinical description of secondary syphilis (with at least one sign 
or symptom) that is laboratory confirmed. 
 
Syphilis, early latent  
 
Clinical description: A subcategory of latent syphilis (a stage of infection caused by T. pallidum 
in which organisms persist in the body of the infected person without causing symptoms or 
signs) when initial infection has occurred within the previous 12 months.  
 
Case classification  
 
Probable:  A person with no clinical signs or symptoms of syphilis who has one of the following:  
 
No past diagnosis of syphilis, AND a reactive nontreponemal test (e.g., VDRL, RPR, or 
equivalent serologic methods), AND a reactive treponemal test (e.g., FTA-ABS, TP-PA, EIA, 
CIA, or equivalent serologic methods),  
 
OR  
 
A current nontreponemal test titer demonstrating fourfold or greater increase from the last 
nontreponemal test titer.  
 
AND  
 
Evidence of having acquired the infection within the previous 12 months based on one or more 
of the following criteria:  
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• Documented seroconversion or fourfold or greater increase in titer of a nontreponemal test 
during the previous 12 months  
• Documented seroconversion of a treponemal test during the previous 12 months  
• A history of symptoms consistent with primary or secondary syphilis during the previous 12 
months  
• A history of sexual exposure to a partner within the previous 12 months who had primary, 
secondary, or early latent syphilis (documented independently as duration < 12 months)  
• Only sexual contact was within the last 12 months (sexual debut)  
 
There is no confirmed case classification for early latent syphilis.  
 
Viral Hepatitis 
 
Hepatitis is inflammation of the liver. It can impair vital liver functions such as processing 
nutrients, filtering the blood and fighting infection. Viral hepatitis is inflammation of the liver 
caused by infection with a virus. In Massachusetts, the most common types of viral hepatitis are 
hepatitis A, hepatitis B and hepatitis C. Hepatitis can also result from heavy alcohol use, toxins, 
some medications, and certain medical conditions.  
 
Chronic HBV 
Confirmed: 
 
IgM antibodies to hepatitis B core antigen (IgM anti-HBc) negative  
 
AND  
 
A positive result on one of the following tests: hepatitis B surface antigen (HBsAg), 
hepatitis B e antigen (HBeAg), or nucleic acid test for hepatitis B virus DNA 
(including qualitative, quantitative and genotype testing),  
 
OR 
 
HBsAg positive or nucleic acid test for hepatitis B virus DNA (including qualitative, 
quantitative and genotype testing), or HBeAg positive two times at least 6 months apart 
(Any combination of these tests performed 6 months apart is acceptable.) 
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Probable: 
A case with a single HBsAg positive or HBV DNA positive (including qualitative, quantitative 
and genotype testing), or HBeAg positive lab result when no IgM anti-HBc results are available 
 
Acute HBV infection 
Clinical Presentation: An acute illness with a discrete onset of symptoms consistent with acute 
viral hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and 
abdominal pain) and either a) jaundice or b) elevated serum alanine aminotransferase levels > 
100 IU/L 
 
Confirmed: 
Clinically compatible case* not known to have chronic hepatitis B and 
HBsAg positive  
 
AND 
 
IgM antibody to hepatitis B core antigen (IgM anti– HBc) positive, if done *  
 
A documented negative hepatitis B surface antigen (HBsAg) laboratory test result within 6 
months prior to a positive test (either HBsAg, Hepatitis B “e” antigen (HBeAg), or hepatitis 
B virus nucleic acid testing (HBV NAT) including genotype) result does NOT require an 
acute clinical presentation to meet the surveillance case definition. 
 
Suspect: 
Positive IgM antibody to hepatitis B core antigen (IgM anti-HBc) that does not meet the clinical 
definition 
 
Note that the year into which a case is categorized is based upon the case’s “Event Date”, which 
is assigned by the following case characteristics, in decreasing order of specificity, dependent on 
availability of information: symptom onset date, specimen collection date, diagnosis date, or case 
report date 
 
Past or Present HCV Infection Newly Reported to MDPH 
Confirmed: 
One or more of the following criteria (except among persons less than 18 months of age, for 
whom only criteria 3 would meet the case classification criteria): 
 
Antibodies to hepatitis C virus (anti-HCV) screening-test-positive with a signal to cut-off ratio 
predictive of a true positive as determined for the particular assay as defined by CDC 
 
OR 
 
Hepatitis C Virus Recombinant Immunoblot Assay (HCV RIBA) positive 
 
OR 
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Nucleic Acid Test (NAT) for HCV RNA positive (including qualitative, quantitative, or 
genotype) 
 
Probable: 
 
Rapid HCV antibody positive test 
 
OR 
 
Anti-HCV screening-test-positive that has not been verified by a more specific  assay or has 
unknown signal to cut-off ratio (regardless of ALT results and acute hepatitis C status) 
 
Acute HCV Infection 
Confirmed: 
Clinically compatible presentation* not known to have chronic HCV with 1 or more of the 
following: 
 
Anti-HCV screening-test-positive with a signal to cut-off ratio predictive of a true positive as 
determined for the particular assay as defined by CDC 
 
OR 
 
HCV RIBA positive 
 
OR 
 
NAT for HCV RNA positive (including qualitative, quantitative, or genotype) 
 
AND 
 if done meets the following two criteria†: 
 
IgM anti-HAV negative AND 
IgM anti-HBV negative 
 
* - A documented negative HCV antibody laboratory result followed within 6 months by 
a positive test result (as described above) does NOT require an acute clinical 
presentation to meet the confirmed case definition 
 
† - From 2007-2013, cases meeting the acute case definition but missing a negative 
HAV & HBV result were classified as Suspect. The case definition change in 2013 
eliminated this requirement. 
 
Suspect: 
 
A documented negative HCV antibody laboratory test result followed within 6-12 
months by a positive test result (as described   above) does NOT require an acute clinical 
presentation to meet the suspect case definition. 
 
Low level viremia (<100,000 IU/mL) not known to have chronic HCV 
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Note that the year into which a case is categorized is based upon the case’s “Event 
Date”, which is assigned by the following case characteristics, in decreasing order of 
specificity, dependent on availability of information: symptom onset date, specimen 
collection date, diagnosis date, or case report date. 
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HIV/AIDS, STD and Viral Hepatitis Program Staff Contact Information 
 
Topic Contact E-Mail Phone 
 
Division of STD Prevention & HIV/AIDS Surveillance, and 
Ratelle STD/HIV Prevention Training Center 
Policy Development and 
Administration 
Kathleen Roosevelt (Director, STD 
Prevention Division) 
Kathleen.roosevelt@state.ma.us 617-983-6941 
Sylvie Ratelle STD/HIV 
Prevention Training Center 
Katherine Hsu (Medical Director) 
Janine Dyer (Deputy Director) 
Katherine.Hsu@state.ma.us 
Janine.Dyer@state.ma.us 
617-983-6948 
617-983-6964 
STD/HIV/AIDS 
Surveillance and 
Epidemiology 
Betsey John (Director, HIV/AIDS and 
STD Surveillance) 
 
Betsey.John@state.ma.us 
 
 
617-983-6570 
 
STD Clinical Services  Katherine Hsu (Medical Director) 
Barbara Coughlin (Public Health Nurse) 
Katherine.Hsu@state.ma.us 
Barbara.Coughlin@state.ma.us 
617-983-6948 
413-586-7525 
STD Disease Intervention 
Field Services and  
STD Partner Notification 
David Goudreau 
(Field Operations Manager) 
Christopher Borger 
(Field Operations Manager) 
David.Goudreau@state.ma.us 
 
Chris.Borger@state.ma.us   
617-983-6835 
 
617-983-6930 
STD Health Education, 
Training, and Prevention 
Brenda Hernandez 
(Special Projects Coordinator) 
  
Brenda.Hernandez@state.ma.us 
 
 
617-983-6943 
 
 
Office of HIV/AIDS 
HIV/AIDS Resource 
Allocation, Policy, and  
Programs  
Dawn Fukuda (Director, Office of 
HIV/AIDS) 
 
Dawn.Fukuda@state.ma.us 
 
 
617-624-5303 
 
 
Health Promotion and 
Disease Prevention 
Services 
 
Linda Goldman, (Director of Health 
Promotion and Disease Prevention)  
 
Linda.Goldman@state.ma.us 
 
617-624-5347 
 
Behavioral Health and 
Community Engagement  
 
Barry Callis  
(Director of Behavioral Health and 
Infectious Disease Prevention 
 
Barry.Callis@state.ma.us 
 
617-624-5316 
 
Viral Hepatitis Program 
Viral Hepatitis 
Surveillance and 
Epidemiology 
Shauna Onofrey (Viral Hepatitis 
Surveillance Coordinator) 
 
Susan Soliva (Epidemiologist) 
Shauna.Onofrey@state.ma.us 
 
 
Susan.Soliva@state.ma.us 
617-983-6776 
 
 
617-983-6883 
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HIV/AIDS, STD, and Viral Hepatitis Resources 
 
Training 
Professional training to community based organizations, local public health departments, and medical providers can 
be requested and is free of charge.  
Type of Training Contact Information and Website 
STD Education, STD Partner Notification, and  
STD Reporting  
617-983-6940 
www.mass.gov/dph/cdc/std 
HIV/AIDS Reporting and Surveillance Projects 
617-983-6560 
www.mass.gov/dph/cdc/aids 
HIV/AIDS Provider Trainings 
617-624-5338 
 www.mass.gov/dph/aids  
Viral Hepatitis Education 
617-983-6800 
http://www.mass.gov/eohhs/gov/departments/dph/programs/id
/epidemiology/hepatitis/hepatitis-c/viral-hepatitis-educational-
materials.html  
STD Diagnosis, Treatment, and Management 
617-983-6945 
www.RatellePTC.org 
Material and Clinical Toolkits  
Health education materials and clinical toolkits can be requested free of charge.  
Type of Material Contact Information and Website 
STD, HIV, Viral Hepatitis Fact Sheets  
617-983-6940 
http://www.mass.gov/eohhs/gov/departments/dph/programs/id/e
pidemiology/factsheets.html#std  
HIV/AIDS Reporting for Health Care Providers 
Brochure 
617-983-6560 
http://www.mass.gov/eohhs/gov/departments/dph/programs/id/h
iv-aids/reporting/  
STD, and HIV Posters and Brochures 
617-983-6800 
https://massclearinghouse.ehs.state.ma.us/  
STD Diagnosis, Treatment, and  
Management Toolkits 
617-983-9645 
www.RatellePTC.org 
  
MDPH and MDPH Funded Websites  
Division of STD Prevention   www.mass.gov/dph/cdc/std 
HIV/AIDS Bureau    www.mass.gov/dph/aids 
HIV/AIDS Surveillance    www.mass.gov/dph/cdc/aids 
Viral Hepatitis Program    www.mass.gov/hepc 
Sylvie Ratelle STD/HIV Prevention Training Center www.RatellePTC.org 
National Websites  
Center for Disease Control and Prevention  www.cdc.gov 
Division of STD Prevention  www.cdc.gov/std 
Division of HIV/AIDS Prevention  www.cdc.gov/hiv 
Division of Viral Hepatitis   www.cdc.gov/hepatitis 
National Network of STD/HIV Prevention  
Training Centers     www.nnptc.org 
CDC funded viral hepatitis online training  http://depts.washington.edu/hepstudy/  
 
